Patents by Inventor Sebastian LETH-PETERSEN

Sebastian LETH-PETERSEN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heterocyclic Compounds and Methods of Use
    Publication number: 20250059205
    Abstract: The present disclosure provides compounds useful for the inhibition of KRAS G12D. The compounds have a general Formula I: (I) wherein the variables of Formula I are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, cancer.
    Type: Application
    Filed: April 28, 2022
    Publication date: February 20, 2025
    Applicant: AMGEN INC.
    Inventors: Brian Alan Lanman, Ryan Paul Wurz, Wei Zhao, Xiaofen Li, Michael M. Yamano, Yunxiao Li, Ning Chen, Birgitte Weinreich Husemoen, Sebastian Leth-Petersen, Jose M. Medina, Kexue Li, Liping Pettus, Rene Rahimoff, Primali Vasundera Navaratne, Huan Rui, Christopher P. Mohr
  • Heterocyclic Compounds and Methods of Use
    Publication number: 20250059179
    Abstract: The present disclosure provides compounds useful for the inhibition of KRAS G12D. The compounds have a general Formula I: (I) wherein the variables of Formula I are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, cancer.
    Type: Application
    Filed: April 28, 2022
    Publication date: February 20, 2025
    Applicant: AMGEN INC.
    Inventors: Brian Alan Lanman, Ryan Paul Wurz, Wei Zhao, Xiaofen Li, Michael M. Yamano, Yunxiao Li, Ning Chen, Sebastian Leth-Petersen, Kexue Li, Liping Pettus, Rene Rahimoff, Primali Vasundera Navaratne, Huan Rui
  • 5-HTagonists for use in treatment of depression
    Patent number: 11642336
    Abstract: The present invention relates to agonists of the 5-HT2A serotonin receptors and their medical uses. In one aspect the invention relates to 5-HT2A agonists of formula (I). In second aspect, the invention relates to selective 5-HT2A agonists of formula (II). In another aspect, the invention relates to mixed 5-HT2A/5-HT2C agonists of formula (III). In yet another aspect, the invention relates to 5-HT2A agonists for use in the treatment of a depressive disorder, more particular a 5-HT2A agonist for the use in the treatment of treatment-resistant depression.
    Type: Grant
    Filed: July 6, 2021
    Date of Patent: May 9, 2023
    Assignee: LOPHORA APS
    Inventors: Jesper Langgaard Kristensen, Anders Asbjørn Jensen, Emil Märcher-Rørsted, Sebastian Leth-Petersen
  • 5-HT2A agonists for use in treatment of depression
    Patent number: 11633390
    Abstract: The present invention relates to agonists of the 5-HT2A serotonin receptors and their medical uses. In one aspect the invention relates to 5-HT2A agonists of formula (I). In second aspect, the invention relates to selective 5-HT2A agonists of formula (II). In another aspect, the invention relates to mixed 5-HT2A/5-HT2C agonists of formula (III). In yet another aspect, the invention relates to 5-HT2A agonists for use in the treatment of a depressive disorder, more particular a 5-HT2A agonist for the use in the treatment of treatment-resistant depression.
    Type: Grant
    Filed: June 16, 2021
    Date of Patent: April 25, 2023
    Assignee: LOPHORA APS
    Inventors: Jesper Langgaard Kristensen, Anders Asbjørn Jensen, Emil Märcher-Rørsted, Sebastian Leth-Petersen
  • 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION
    Publication number: 20220062257
    Abstract: The present invention relates to agonists of the 5-HT2A serotonin receptors and their medical uses. In one aspect the invention relates to 5-HT2A agonists of formula (I). In second aspect, the invention relates to selective 5-HT2A agonists of formula (II). In another aspect, the invention relates to mixed 5-HT2A/5-HT2C agonists of formula (III). In yet another aspect, the invention relates to 5-HT2A agonists for use in the treatment of a depressive disorder, more particular a 5-HT2A agonist for the use in the treatment of treatment-resistant depression.
    Type: Application
    Filed: June 16, 2021
    Publication date: March 3, 2022
    Applicant: Lophora ApS
    Inventors: Jesper Langgaard KRISTENSEN, Anders Asbjørn Jensen, Emil Märcher-Rørsted, Sebastian Leth-Petersen
  • 5-HTagonists for use in treatment of depression
    Patent number: 11246860
    Abstract: The present invention relates to agonists of the 5-HT2A serotonin receptors and their medical uses. In one aspect the invention relates to 5-HT2A agonists of formula (I). In second aspect, the invention relates to selective 5-HT2A agonists of formula (II). In another aspect, the invention relates to mixed 5-HT2A/5-HT2C agonists of formula (III). In yet another aspect, the invention relates to 5-HT2A agonists for use in the treatment of a depressive disorder, more particular a 5-HT2A agonist for the use in the treatment of treatment-resistant depression.
    Type: Grant
    Filed: November 5, 2020
    Date of Patent: February 15, 2022
    Assignee: Lophora ApS
    Inventors: Jesper Langgaard Kristensen, Anders Asbjørn Jensen, Emil Märcher-Rørsted, Sebastian Leth-Petersen
  • 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION
    Publication number: 20210330658
    Abstract: The present invention relates to agonists of the 5-HT2A serotonin receptors and their medical uses. In one aspect the invention relates to 5-HT2A agonists of formula (I). In second aspect, the invention relates to selective 5-HT2A agonists of formula (II). In another aspect, the invention relates to mixed 5-HT2A/5-HT2C agonists of formula (III). In yet another aspect, the invention relates to 5-HT2A agonists for use in the treatment of a depressive disorder, more particular a 5-HT2A agonist for the use in the treatment of treatment-resistant depression.
    Type: Application
    Filed: July 6, 2021
    Publication date: October 28, 2021
    Applicant: Lophora ApS
    Inventors: Jesper Langgaard KRISTENSEN, Anders Asbjørn JENSEN, Emil MÄRCHER-RØRSTED, Sebastian LETH-PETERSEN
  • 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION
    Publication number: 20210137908
    Abstract: The present invention relates to agonists of the 5-HT2A serotonin receptors and their medical uses. In one aspect the invention relates to 5-HT2A agonists of formula (I). In second aspect, the invention relates to selective 5-HT2A agonists of formula (II). In another aspect, the invention relates to mixed 5-HT2A/5-HT2C agonists of formula (III). In yet another aspect, the invention relates to 5-HT2A agonists for use in the treatment of a depressive disorder, more particular a 5-HT2A agonist for the use in the treatment of treatment-resistant depression.
    Type: Application
    Filed: November 5, 2020
    Publication date: May 13, 2021
    Applicant: Lophora ApS
    Inventors: Jesper Langgaard KRISTENSEN, Anders Asbjørn JENSEN, Emil MÄRCHER-RØRSTED, Sebastian LETH-PETERSEN